In This Section

Home / Learn / Precision Medicine / Treatment / Adverse Events / Project ECHO®: Tele-mentoring to Manage Immune-related Adverse Events in Patients Receiving Cancer Immunotherapies

Project ECHO®: Tele-mentoring to Manage Immune-related Adverse Events in Patients Receiving Cancer Immunotherapies

Immunotherapies are rapidly advancing and yielding impressive clinical benefits in a growing number of cancers, and as new drugs are introduced and clinical indications are expanded for existing drugs in this class, immunotherapy usage in cancer care is expected to increase. However, with this growth comes new challenges for community cancer care programs, as oncologists and multidisciplinary care teams must navigate the practical challenges of immunotherapies, including the management of immune-related adverse events that can sometimes accompany these therapies.
According to the National Cancer Institute, 80% of patients with cancer are treated in community hospitals each year in the United States, which is why it is critical for community care teams to be prepared to promptly diagnose, monitor, and manage immune-related adverse events; these events may rapidly progress to severe, life-threatening, or fatal and may require discontinuing therapy and/or frequent hospitalizations.

Optimal management of immune-related adverse events often requires expertise (e.g., in rheumatology, pulmonology, cardiology, ophthalmology, and others) outside the realm of oncology, and it may be particularly challenging for community practitioners to identify and access specialists who can provide guidance on management of immune-related adverse events.

To address this growing need, the Association of Community Cancer Centers (ACCC) has launched Project ECHO®️: Tele-mentoring to Manage Immune-related Adverse Events in Patients Receiving Cancer Immunotherapies. This initiative fosters opportunities for community oncology programs to participate in tele-mentoring with a virtual team of toxicity management and assessment specialists (including rheumatologists, endocrinologists, cardiologists, dermatologists, neurologists, hematologists, pulmonologists, ophthalmologists, gastroenterologists, and infectious disease specialists) using the Project ECHO®️ model.

If you could benefit from expert advice on the optimal management of Immune-related Adverse Events (irAEs), please join ACCC and Boston University for monthly tele-mentoring sessions where you can receive guidance on clinical cases and have your questions answered by expert faculty.

Target Audience: Oncologists, oncology advanced practice providers (nurse practitioners, physician assistants), oncology pharmacists, oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with cancer immunotherapies.

When: Third Tuesday of every month from 3:00 – 4:00 PM ET, beginning September 20, 2022. Participants can join the virtual program at any time.

September 20, 2022
February 21, 2023
October 18, 2022
March 21, 2023
November 15, 2022
April 18, 2023
January 17, 2023
May 16, 2023

Free Registration

Registration Instructions

A Zoom link will be provided upon registration. Please click the “Add to Calendar” option after registering to add this series on your calendar. To join each session, use the Zoom link in the calendar invitation so you do not have to complete the registration form again.

Questions? Contact Mary Stanley, Program Manager.

Learning Objectives

At the end of this educational activity, participants will be able to:

  • Apply evidence-based practices for the monitoring and management of irAEs in patients receiving cancer immunotherapies
  • Improve coordination and communication with non-oncology specialists and with patients/caregivers to manage irAEs in patients receiving cancer immunotherapies
  • Review strategies for providing equitable care for underserved patients receiving cancer immunotherapies

Steering Committee

Jocelyn Mohs
Jocelyn Mohs, PharmD, BCOP
Pharmacy Manager; PGY-2 Oncology Pharmacy Residency Program Director
Sanford Roger Maris Cancer Center
Fargo, ND

Jocelyn Mohs, PharmD, BCOP, is a pharmacy manager at the Infusion Clinic Pharmacy, Sanford Roger Maris Cancer Center in Fargo, North Dakota. She serves as the residency program director for the newly established PGY-2 Oncology Pharmacy Residency at the same center.   

Dr. Mohs earned her PharmD at Creighton University in Omaha, Nebraska. She completed a PGY1 pharmacy practice residency at the Minneapolis VA Medical Center in Minneapolis, Minnesota and a PGY2 oncology specialty residency at the University of Minnesota Medical Center, Fairview in Minneapolis and Maple Grove, Minnesota. 

Ryan Weight
Ryan Weight, DO, MS
Assistant Professor, Department of Medical Oncology
University of Colorado
Denver, Colorado

Ryan Weight, DO, MS, joined the University of Colorado School of Medicine faculty in 2019 as an assistant professor of medicine with a focus on the treatment of skin malignancies, including melanoma. Prior to this appointment, Dr. Weight served as an assistant professor of medicine at Thomas Jefferson University School of Medicine in Philadelphia.  In 2017, Dr. Weight was appointed leader of the cutaneous malignancy service line within the melanoma division of medical oncology. Dr. Weight established and served as co-director of the Complex Cutaneous Oncology Multidisciplinary Clinic in the Center for Heritable and Connective Tissue Skin Diseases, which brought together dermatology and medical oncology services for the treatment of dysplastic nevus syndrome, patients with a genetic predisposition to skin cancer, erythema bullosum, and others.

Dr. Weight has an interest in the management of immune-related adverse events caused by immune-activating therapies commonly used for the treatment of skin cancers. He served as director of the Immuno-Oncology Clinical Working Group at Thomas Jefferson University (2016- 2018), and as principal investigator for a number of clinical trials focused on the treatment of melanoma, including early phase trials. He has co-authored a multi-center adjuvant study of Nivolumab for the treatment of resected high-risk melanoma patients. 

Laura S. Wood
Laura Wood, RN, MSN, OCN
Oncology Nurse Specialist
Retired from Clinical Practice
Cleveland, OH

Laura S. Wood RN, MSN, OCN is an oncology nurse with over 30 years of experience in the care of patients with renal and genitourinary cancers and oncology clinical trial coordination. Prior to leaving clinical practice, Laura was the Renal Cancer Clinical Research Coordinator at the Cleveland Clinic Cancer Center Immunotherapy Education Committee, and the immune-related Adverse Event Tumor Board. She is active in the local and national Oncology Nursing Society, the American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer. 

Ms. Wood completed both her bachelor’s and master’s degrees in nursing at Kent State University in Kent, Ohio. A national and international lecturer on topics related to oncology nursing.

Supported by Bristol Myers Squibb. These activities will be CME/CPE/CNE-certified.

Our Supporter